CCL5 and neoplasm: Tumor‐derived PGE2 reduces the ability of NK to recruit and activate immune cells by inhibiting the release of XCL1 and CCL5 and the expression of their receptors on cDC1, and induces skewing of NK cells toward an immunosuppressive state, affecting NK migration and release of cytotoxic enzymes